

EVIDENCE FOR THE INTEGRATION OF TOTAL AND FREE **TESTOSTERONE IN MANAGEMENT OF PROSTATE CANCER** Linda My Huynh MSc, Maxwell Towe BS, Farouk M. El-Khatib MD, Mohamad M Osman BS, Faysal Yafi MD, Thomas Ahlering MD UC Irvine Health; University of California – Irvine, Orange, CA USA



### **1. Introduction and Objectives**

Within the context of prostate cancer (PC), there has been a historic fear of high serum testosterone, a hesitance towards testosterone supplementation, and a resultant lack of systematized testosterone screening. Herein, we seek to investigate the utility of serum total and calculated free testosterone (cFT) in PC management.

## 2. Materials and Methods

- 830 patients underwent RP, with prospectively-drawn total testosterone (TT), sex hormone binding globulin (SHBG) and calculated free testosterone (cFT).
- Impact of age on TT, cFT, and SHBG was assessed with linear regression modeling and R<sup>2</sup>

## 3. Age-Stratified Trends of TT, cFT, and SHBG

Figure 1. Effect of age on androgens.





- Correlation of patients with low cFT with adverse oncologic characteristics (i.e. high-risk Gleason grade 9-10, extraprostatic extension, and seminal vesicle invasion) was assessed with receiver-operator characteristic (ROC) curves.
- Logistic regression was used to assess effect size of preoperative cFT on oncologic characteristics.

## 3. Results – Effects of Endogenous cFT on Disease Characteristics, Univariate Analysis

#### **Table 1.** Demographic Characteristics of 830 Patients

|   | Mean  | SD    |
|---|-------|-------|
| Age (years)                             | 62.7  | 7.5   |
| BMI (kg/m²)                             | 27.2  | 3.7   |
| Preoperative PSA (ng/mL)                | 7.9   | 6.2   |
| Prostate Volume (mL)                    | 54.7  | 20.3  |
| Preoperative Total Testosterone (ng/dL) | 361.2 | 167.6 |
| Preoperative SHBG (nmol/L)              | 46.0  | 21.7  |
| Preoperative Free Testosterone (ng/dL)  | 6.1   | 3.2   |
|   | Ν     | %     |
| Pathologic Grade                        |       |       |
| 1 (3+3)                                 | 165   | 20%   |
| 2 (3+4)                                 | 331   | 40%   |
| 3 (4+3)                                 | 190   | 23%   |
| 4 (4+4)                                 | 45    | 5%    |
| 5 (9-10)                                | 99    | 12%   |
| Pathologic Stage                        |       |       |
| pT2                                     | 549   | 66%   |
| pT3                                     | 270   | 33%   |
| pT4                                     | 11    | 1%    |

 Table 2a. Gleason Grade Group Prevalence by cFT Quartile



# **Table 2b.** P-stage Prevalence by cFT Quartile



## 3. Results – Effects of Endogenous cFT on Disease Characteristics, Multivariate Analysis

**Table 3.** Logistic Regression of cFT as a predictor of high-risk Gleason

Figure 1. ROC curve of Gleason Grade Group 9-10

95% CI B S.E. Sig. OR Wald Lower Upper



In ROC analysis, preoperative FT was an independent predictor of GGG 9-10, with an area under the curve of 0.6988 (p=0.018, 95%CI: 0.381 – 0.489). Of note, age and preoperative PSA were also independent predictors.



In multivariate analysis, lower FT was a significant predictor of high-risk score 9-10 (OR: 0.912, 95% CI: 0.836-0.994, p=0.036).

#### **5.** Conclusion

Low cFT is a risk factor for high grade and high stage PC. These results have implications for the current recommendations for prostate cancer risk analysis and stratification. Free and total testosterone levels should be assessed in all men with prostate cancer.

